Evolving Role of the Thoracic Oncologic Surgeon in the Era of Molecular and Immune-Targeted Therapies for Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 5386
Special Issue Editor
Interests: neoplasms; therapeutics; survival; non-small cell lung carcinoma; neoplasm metastasis; lung neoplasms; Ischemia; recurrence; esophageal neoplasms
Special Issue Information
Dear Colleagues,
The advent of molecular-targeted therapy and immune checkpoint inhibitors has revolutionized the treatment of patients with advanced-stage lung cancer over the past 10 years. Recent promising studies have now begun to investigate the use of immunotherapy and drug-targeted oncogenic driver mutations in patients with operable lung cancer. With the expansion of these treatments to the neoadjuvant setting, it will be critical for the thoracic oncologic surgeon to understand and incorporate preoperative molecular testing and define clinical algorithms aimed at reducing surgical risk in patients who have undergone treatment with molecular targeted therapy and immunotherapy.
This Special Edition of the Cancers journal will highlight original research and comprehensive reviews related to preoperative tumor molecular characterization, as well as the incorporation of targeted therapy and/or immunotherapy in the treatment of patients with lung cancer undergoing curative resection.
Dr. Matthew D. Taylor
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- immunotherapy
- neoadjuvant
- targeted therapy
- resection
- molecular target
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
